Aspire Biopharma Holdings (ASBP) Other Non-Current Assets (2022)
Aspire Biopharma Holdings' (ASBP) quarterly Other Non-Current Assets came in at $80170.0 in Q4 2022, down 65.27% quarter-over-quarter from $230848.0 in Q3 2022.
Powered by 
Analysis
Aspire Biopharma Holdings (ASBP) Other Non-Current Assets (2022) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Other Non-Current Assets for 1 consecutive years, with $80170.0 the latest figure, recorded in Q4 2022.
- On a quarterly basis, Other Non-Current Assets changed N/A year-over-year to $80170.0 in Q4 2022; TTM through Dec 2022 was $80170.0, a N/A change from a year earlier, with the FY2022 full-year figure at $80170.0, changed N/A from the prior year.
- Other Non-Current Assets was $80170.0 for Q4 2022 at Aspire Biopharma Holdings, down from $230848.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $530459.0 in Q1 2022 and troughed at $80170.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 618.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 124.00 Mn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | 29.59 Mn |
| 10 | Aspire Biopharma Holdings | 64.13 Mn | 51.96 Mn | -30,086.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 80,170.00 |
| Sep 30, 2022 | 230,848.00 |
| Jun 30, 2022 | 381,472.00 |
| Mar 31, 2022 | 530,459.00 |